Clinical Trial Detail

NCT ID NCT02584478
Title Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Advenchen Laboratories, LLC
Indications

fallopian tube cancer

cervical cancer

uterine cancer

endometrial cancer

cervical adenosquamous carcinoma

endometrioid ovary carcinoma

cervical squamous cell carcinoma

ovary adenocarcinoma

peritoneum cancer

ovarian cancer

ovarian clear cell adenocarcinoma

cervical adenocarcinoma

ovarian seromucinous carcinoma

ovary serous adenocarcinoma

Therapies

Anlotinib + Carboplatin + Paclitaxel

Age Groups: adult senior

No variant requirements are available.